by Team Small News | Aug 26, 2025 | Aurobindo Pharma, Cipla, Lupin, Pharma, Sun Pharma
The Saudi Arabia Generic Drugs Market is expected to grow significantly, reaching US$ 8.11 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 8.02% from 2025 to 2033. This growth is attributed to increased healthcare needs, government efforts to reduce... by Team Small News | Aug 25, 2025 | Cipla, Glenmark, Lupin, Mankind, Pharma
Several Indian pharmaceutical companies, including Cipla, Glenmark, Lupin, and Mankind Pharma, have demerged their consumer healthcare businesses to focus on growth and expansion. This trend is also being seen globally, with companies like GlaxoSmithKline, Johnson and... by Team Small News | Jul 18, 2025 | Cipla, Pharma
Cipla, a leading pharmaceutical company, is confident in its ability to withstand the potential impact of tariff threats on its business. In a recent interview, Cipla’s CEO, Umang Vohra, emphasized that the company has “one of the most well-diversified... by Team Small News | Jul 12, 2025 | Cipla, Dr Reddy's, Lupin, Pfizer, Pharma
The Global Digoxin Market study, recently introduced by HTF MI, provides a comprehensive overview of the product and industry scope, as well as an in-depth analysis of the market outlook and status from 2025 to 2031. The market is segmented by key regions, including... by Team Small News | Jul 4, 2025 | Cipla, Glenmark, Lupin, Mankind, Pharma
Lupin, a leading pharmaceutical company, has created a new subsidiary called LupinLife Consumer Healthcare Ltd to house its consumer healthcare business. This move is in line with a growing trend among pharmaceutical companies, both in India and globally, to separate... by Team Small News | May 31, 2025 | Cipla, Pharma
The US Food and Drug Administration (USFDA) has issued a single observation for Cipla’s Bommasandra facility, which is a pharmaceutical manufacturing plant located in Karnataka, India. The observation was made after the USFDA conducted an inspection of the...